Lung Cancer Therapeutics Market is expected to Grow at 9.62% Through 2030F

Increasing demand for immunotherapy and targeted therapy along with the rising incidence of Lung Cancers driving the growth of the Global Lung Cancer Therapeutics Market in the forecast period, 2026-2030.

According to the TechSci Research report, “Lung Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F”, Global Lung Cancer Therapeutics Market was valued at USD 25.43 billion in 2024 and is expected to reach USD 40.55 billion by 2030 with a CAGR of 9.62%. The factors responsible for the growth of the market are the availability of highly effective drugs, a surge in the prevalence of sedentary lifestyles, and a rising need for customized therapy. Further, the rising demand for personalized medicines and immunotherapy is fueling market expansion. In addition, regulatory approval of various medicines and drugs in the lung cancer treatment market is anticipated to support the growth of the market.

However, it is anticipated that the main factors limiting the overall growth of the global lung cancer therapeutics market size are the lack of effective treatment alternatives, the wide accessibility of generic vital pharmaceuticals, and a significant unmet evaluation demand. Further, radiotherapy and chemotherapy treatments carry a high risk of side effects which is expected to limit market expansion.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on the "Global Lung Cancer Therapeutics Market”

The global lung cancer therapeutics market is segmented based on cancer cell type and treatment.

Based on the Treatment segment, Immunotherapy is Fastest Growing Segment in the global lung cancer therapeutics market, largely due to its significant advancements and effectiveness in treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, have revolutionized treatment by enhancing the body’s immune system to recognize and attack cancer cells. Immunotherapy has shown improved survival rates, particularly in patients with advanced-stage lung cancer, making it a preferred treatment choice. While chemotherapy and radiation therapy remain important, especially in the treatment of SCLC and as part of combination therapies, they are being gradually overshadowed by immunotherapy and targeted therapies. Targeted therapies, such as EGFR and ALK inhibitors, are also gaining significant traction, especially for patients with specific genetic mutations. Other treatments, like surgery or palliative care, play a role but are less dominant in the market compared to the growing adoption of immunotherapy and targeted therapies.

Based on region, Asia-Pacific is the fastest-growing region in the global lung cancer therapeutics market due to several key factors. The region has a high and rising incidence of lung cancer, driven by increasing smoking rates, air pollution, and aging populations, particularly in countries like China and India. The growing healthcare infrastructure, expanding access to advanced diagnostic tools, and increasing government initiatives for cancer care are boosting early detection and treatment rates. Economic development across the region is also enabling greater investment in healthcare and pharmaceutical innovation. The international and regional pharmaceutical companies are expanding their presence through partnerships and clinical trials, accelerating the availability of advanced therapies such as targeted treatments and immunotherapies. Rising awareness and improving healthcare reimbursement policies are further supporting patient access to these innovative treatments, driving rapid market growth across the Asia-Pacific region.

Major companies operating in the global lung cancer therapeutics market are:

·         AstraZeneca Plc

·         Boehringer Ingelheim International GmbH

·         Bristol-Myers Squibb Company

·         Eli Lilly and Company

·         F. Hoffmann-La Roche AG.

·         Merck & Co

·         Pfizer Inc.

·         Allergan Inc.

·         Teva Pharmaceutical Industries Ltd.

·         Abbvie, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

North America currently leads in terms of adoption due to strong healthcare infrastructure and access to cutting-edge treatments. However, the Asia-Pacific region is rapidly emerging as a key growth area, driven by increasing healthcare investment and a rising patient base. Despite these opportunities, challenges such as high treatment costs, limited access in lower-income regions, and regulatory complexities remain. Continued research, innovation, and collaborative efforts are essential for expanding access and improving outcomes for lung cancer patients worldwide", said Mr. Karan Chechi, Research Director, of TechSci Research, a research-based management consulting firm.

“Lung Cancer Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments), By Region & Competition 2020-2030F,” has evaluated the future growth potential of global lung cancer therapeutics market and provides statistics & information on market size, structure, and future market growth. the report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the global lung cancer therapeutics market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com